Global Graft Versus Host Disease Treatment Market 2022 by Company, Regions, Type and Application, Forecast to 2028

Page: 113

Published Date: 02 Apr 2022

Category: Medical Care

PDF Download

Get FREE Sample

Customize Request

Description
Table of Contents
Table of Figures
Research Methodology
Companies Mentioned
Related Reports
Product Tags

Description

The Graft Versus Host Disease Treatment market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

According to our (Global Info Research) latest study, due to COVID-19 pandemic, the global Graft Versus Host Disease Treatment market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of USD million by 2028 with a CAGR of % during forecast period 2022-2028. Acute GVHD accounting for % of the Graft Versus Host Disease Treatment global market in 2021, is projected to value USD million by 2028, growing at a % CAGR in next six years. While Etanercept segment is altered to a % CAGR between 2022 and 2028.

Global key companies of Graft Versus Host Disease Treatment include AbbVie Inc., Acrofan, Astellas Pharma Inc., Bristol-Myers Squibb Company, and ElsaLys Biotech SA, etc. In terms of revenue, the global top four players hold a share over % in 2021.

Market segmentation
Graft Versus Host Disease Treatment market is split by Type and by Application. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type, covers
Etanercept
Monoclonal Antibodies
Thalidomide
Tyrosine Kinase Inhibitors
mTOR Inhibitors

Market segment by Application, can be divided into
Acute GVHD
Chronic GVHD
Prophylaxis GVHD

Market segment by players, this report covers
AbbVie Inc.
Acrofan
Astellas Pharma Inc.
Bristol-Myers Squibb Company
ElsaLys Biotech SA
F. Hoffmann-La Roche AG
Johnson & Johnson
Mallinckrodft PLC
Merck & Co., Inc.
Mesoblast Limited
Neovii Biotech GmbH
Novartis AG
Ocugen, Inc.
Pfizer Inc
Pluristem Therapeutics Inc.
Samedan Ltd
Sanofi SA
Soligenix, Inc.

Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)

The content of the study subjects, includes a total of 12 chapters:
Chapter 1, to describe Graft Versus Host Disease Treatment product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top players of Graft Versus Host Disease Treatment, with revenue, gross margin and global market share of Graft Versus Host Disease Treatment from 2019 to 2022.
Chapter 3, the Graft Versus Host Disease Treatment competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with revenue and growth rate by Type, application, from 2017 to 2028.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2017 to 2022.and Graft Versus Host Disease Treatment market forecast, by regions, type and application, with revenue, from 2023 to 2028.
Chapter 11 and 12, to describe Graft Versus Host Disease Treatment research findings and conclusion, appendix and data source.

Table of Contents

1 Market Overview
    1.1 Product Overview and Scope of Graft Versus Host Disease Treatment
    1.2 Classification of Graft Versus Host Disease Treatment by Type
        1.2.1 Overview: Global Graft Versus Host Disease Treatment Market Size by Type: 2017 Versus 2021 Versus 2028
        1.2.2 Global Graft Versus Host Disease Treatment Revenue Market Share by Type in 2021
        1.2.3 Etanercept
        1.2.4 Monoclonal Antibodies
        1.2.5 Thalidomide
        1.2.6 Tyrosine Kinase Inhibitors
        1.2.7 mTOR Inhibitors
    1.3 Global Graft Versus Host Disease Treatment Market by Application
        1.3.1 Overview: Global Graft Versus Host Disease Treatment Market Size by Application: 2017 Versus 2021 Versus 2028
        1.3.2 Acute GVHD
        1.3.3 Chronic GVHD
        1.3.4 Prophylaxis GVHD
    1.4 Global Graft Versus Host Disease Treatment Market Size & Forecast
    1.5 Global Graft Versus Host Disease Treatment Market Size and Forecast by Region
        1.5.1 Global Graft Versus Host Disease Treatment Market Size by Region: 2017 VS 2021 VS 2028
        1.5.2 Global Graft Versus Host Disease Treatment Market Size by Region, (2017-2022)
        1.5.3 North America Graft Versus Host Disease Treatment Market Size and Prospect (2017-2028)
        1.5.4 Europe Graft Versus Host Disease Treatment Market Size and Prospect (2017-2028)
        1.5.5 Asia-Pacific Graft Versus Host Disease Treatment Market Size and Prospect (2017-2028)
        1.5.6 South America Graft Versus Host Disease Treatment Market Size and Prospect (2017-2028)
        1.5.7 Middle East and Africa Graft Versus Host Disease Treatment Market Size and Prospect (2017-2028)
    1.6 Market Drivers, Restraints and Trends
        1.6.1 Graft Versus Host Disease Treatment Market Drivers
        1.6.2 Graft Versus Host Disease Treatment Market Restraints
        1.6.3 Graft Versus Host Disease Treatment Trends Analysis

2 Company Profiles
    2.1 AbbVie Inc.
        2.1.1 AbbVie Inc. Details
        2.1.2 AbbVie Inc. Major Business
        2.1.3 AbbVie Inc. Graft Versus Host Disease Treatment Product and Solutions
        2.1.4 AbbVie Inc. Graft Versus Host Disease Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
        2.1.5 AbbVie Inc. Recent Developments and Future Plans
    2.2 Acrofan
        2.2.1 Acrofan Details
        2.2.2 Acrofan Major Business
        2.2.3 Acrofan Graft Versus Host Disease Treatment Product and Solutions
        2.2.4 Acrofan Graft Versus Host Disease Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
        2.2.5 Acrofan Recent Developments and Future Plans
    2.3 Astellas Pharma Inc.
        2.3.1 Astellas Pharma Inc. Details
        2.3.2 Astellas Pharma Inc. Major Business
        2.3.3 Astellas Pharma Inc. Graft Versus Host Disease Treatment Product and Solutions
        2.3.4 Astellas Pharma Inc. Graft Versus Host Disease Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
        2.3.5 Astellas Pharma Inc. Recent Developments and Future Plans
    2.4 Bristol-Myers Squibb Company
        2.4.1 Bristol-Myers Squibb Company Details
        2.4.2 Bristol-Myers Squibb Company Major Business
        2.4.3 Bristol-Myers Squibb Company Graft Versus Host Disease Treatment Product and Solutions
        2.4.4 Bristol-Myers Squibb Company Graft Versus Host Disease Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
        2.4.5 Bristol-Myers Squibb Company Recent Developments and Future Plans
    2.5 ElsaLys Biotech SA
        2.5.1 ElsaLys Biotech SA Details
        2.5.2 ElsaLys Biotech SA Major Business
        2.5.3 ElsaLys Biotech SA Graft Versus Host Disease Treatment Product and Solutions
        2.5.4 ElsaLys Biotech SA Graft Versus Host Disease Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
        2.5.5 ElsaLys Biotech SA Recent Developments and Future Plans
    2.6 F. Hoffmann-La Roche AG
        2.6.1 F. Hoffmann-La Roche AG Details
        2.6.2 F. Hoffmann-La Roche AG Major Business
        2.6.3 F. Hoffmann-La Roche AG Graft Versus Host Disease Treatment Product and Solutions
        2.6.4 F. Hoffmann-La Roche AG Graft Versus Host Disease Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
        2.6.5 F. Hoffmann-La Roche AG Recent Developments and Future Plans
    2.7 Johnson & Johnson
        2.7.1 Johnson & Johnson Details
        2.7.2 Johnson & Johnson Major Business
        2.7.3 Johnson & Johnson Graft Versus Host Disease Treatment Product and Solutions
        2.7.4 Johnson & Johnson Graft Versus Host Disease Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
        2.7.5 Johnson & Johnson Recent Developments and Future Plans
    2.8 Mallinckrodft PLC
        2.8.1 Mallinckrodft PLC Details
        2.8.2 Mallinckrodft PLC Major Business
        2.8.3 Mallinckrodft PLC Graft Versus Host Disease Treatment Product and Solutions
        2.8.4 Mallinckrodft PLC Graft Versus Host Disease Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
        2.8.5 Mallinckrodft PLC Recent Developments and Future Plans
    2.9 Merck & Co., Inc.
        2.9.1 Merck & Co., Inc. Details
        2.9.2 Merck & Co., Inc. Major Business
        2.9.3 Merck & Co., Inc. Graft Versus Host Disease Treatment Product and Solutions
        2.9.4 Merck & Co., Inc. Graft Versus Host Disease Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
        2.9.5 Merck & Co., Inc. Recent Developments and Future Plans
    2.10 Mesoblast Limited
        2.10.1 Mesoblast Limited Details
        2.10.2 Mesoblast Limited Major Business
        2.10.3 Mesoblast Limited Graft Versus Host Disease Treatment Product and Solutions
        2.10.4 Mesoblast Limited Graft Versus Host Disease Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
        2.10.5 Mesoblast Limited Recent Developments and Future Plans
    2.11 Neovii Biotech GmbH
        2.11.1 Neovii Biotech GmbH Details
        2.11.2 Neovii Biotech GmbH Major Business
        2.11.3 Neovii Biotech GmbH Graft Versus Host Disease Treatment Product and Solutions
        2.11.4 Neovii Biotech GmbH Graft Versus Host Disease Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
        2.11.5 Neovii Biotech GmbH Recent Developments and Future Plans
    2.12 Novartis AG
        2.12.1 Novartis AG Details
        2.12.2 Novartis AG Major Business
        2.12.3 Novartis AG Graft Versus Host Disease Treatment Product and Solutions
        2.12.4 Novartis AG Graft Versus Host Disease Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
        2.12.5 Novartis AG Recent Developments and Future Plans
    2.13 Ocugen, Inc.
        2.13.1 Ocugen, Inc. Details
        2.13.2 Ocugen, Inc. Major Business
        2.13.3 Ocugen, Inc. Graft Versus Host Disease Treatment Product and Solutions
        2.13.4 Ocugen, Inc. Graft Versus Host Disease Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
        2.13.5 Ocugen, Inc. Recent Developments and Future Plans
    2.14 Pfizer Inc
        2.14.1 Pfizer Inc Details
        2.14.2 Pfizer Inc Major Business
        2.14.3 Pfizer Inc Graft Versus Host Disease Treatment Product and Solutions
        2.14.4 Pfizer Inc Graft Versus Host Disease Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
        2.14.5 Pfizer Inc Recent Developments and Future Plans
    2.15 Pluristem Therapeutics Inc.
        2.15.1 Pluristem Therapeutics Inc. Details
        2.15.2 Pluristem Therapeutics Inc. Major Business
        2.15.3 Pluristem Therapeutics Inc. Graft Versus Host Disease Treatment Product and Solutions
        2.15.4 Pluristem Therapeutics Inc. Graft Versus Host Disease Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
        2.15.5 Pluristem Therapeutics Inc. Recent Developments and Future Plans
    2.16 Samedan Ltd
        2.16.1 Samedan Ltd Details
        2.16.2 Samedan Ltd Major Business
        2.16.3 Samedan Ltd Graft Versus Host Disease Treatment Product and Solutions
        2.16.4 Samedan Ltd Graft Versus Host Disease Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
        2.16.5 Samedan Ltd Recent Developments and Future Plans
    2.17 Sanofi SA
        2.17.1 Sanofi SA Details
        2.17.2 Sanofi SA Major Business
        2.17.3 Sanofi SA Graft Versus Host Disease Treatment Product and Solutions
        2.17.4 Sanofi SA Graft Versus Host Disease Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
        2.17.5 Sanofi SA Recent Developments and Future Plans
    2.18 Soligenix, Inc.
        2.18.1 Soligenix, Inc. Details
        2.18.2 Soligenix, Inc. Major Business
        2.18.3 Soligenix, Inc. Graft Versus Host Disease Treatment Product and Solutions
        2.18.4 Soligenix, Inc. Graft Versus Host Disease Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
        2.18.5 Soligenix, Inc. Recent Developments and Future Plans

3 Market Competition, by Players
    3.1 Global Graft Versus Host Disease Treatment Revenue and Share by Players (2019, 2020, 2021, and 2022)
    3.2 Market Concentration Rate
        3.2.1 Top 3 Graft Versus Host Disease Treatment Players Market Share in 2021
        3.2.2 Top 10 Graft Versus Host Disease Treatment Players Market Share in 2021
        3.2.3 Market Competition Trend
    3.3 Graft Versus Host Disease Treatment Players Head Office, Products and Services Provided
    3.4 Graft Versus Host Disease Treatment Mergers & Acquisitions
    3.5 Graft Versus Host Disease Treatment New Entrants and Expansion Plans

4 Market Size Segment by Type
    4.1 Global Graft Versus Host Disease Treatment Revenue and Market Share by Type (2017-2022)
    4.2 Global Graft Versus Host Disease Treatment Market Forecast by Type (2023-2028)

5 Market Size Segment by Application
    5.1 Global Graft Versus Host Disease Treatment Revenue Market Share by Application (2017-2022)
    5.2 Global Graft Versus Host Disease Treatment Market Forecast by Application (2023-2028)

6 North America by Country, by Type, and by Application
    6.1 North America Graft Versus Host Disease Treatment Revenue by Type (2017-2028)
    6.2 North America Graft Versus Host Disease Treatment Revenue by Application (2017-2028)
    6.3 North America Graft Versus Host Disease Treatment Market Size by Country
        6.3.1 North America Graft Versus Host Disease Treatment Revenue by Country (2017-2028)
        6.3.2 United States Graft Versus Host Disease Treatment Market Size and Forecast (2017-2028)
        6.3.3 Canada Graft Versus Host Disease Treatment Market Size and Forecast (2017-2028)
        6.3.4 Mexico Graft Versus Host Disease Treatment Market Size and Forecast (2017-2028)

7 Europe by Country, by Type, and by Application
    7.1 Europe Graft Versus Host Disease Treatment Revenue by Type (2017-2028)
    7.2 Europe Graft Versus Host Disease Treatment Revenue by Application (2017-2028)
    7.3 Europe Graft Versus Host Disease Treatment Market Size by Country
        7.3.1 Europe Graft Versus Host Disease Treatment Revenue by Country (2017-2028)
        7.3.2 Germany Graft Versus Host Disease Treatment Market Size and Forecast (2017-2028)
        7.3.3 France Graft Versus Host Disease Treatment Market Size and Forecast (2017-2028)
        7.3.4 United Kingdom Graft Versus Host Disease Treatment Market Size and Forecast (2017-2028)
        7.3.5 Russia Graft Versus Host Disease Treatment Market Size and Forecast (2017-2028)
        7.3.6 Italy Graft Versus Host Disease Treatment Market Size and Forecast (2017-2028)

8 Asia-Pacific by Region, by Type, and by Application
    8.1 Asia-Pacific Graft Versus Host Disease Treatment Revenue by Type (2017-2028)
    8.2 Asia-Pacific Graft Versus Host Disease Treatment Revenue by Application (2017-2028)
    8.3 Asia-Pacific Graft Versus Host Disease Treatment Market Size by Region
        8.3.1 Asia-Pacific Graft Versus Host Disease Treatment Revenue by Region (2017-2028)
        8.3.2 China Graft Versus Host Disease Treatment Market Size and Forecast (2017-2028)
        8.3.3 Japan Graft Versus Host Disease Treatment Market Size and Forecast (2017-2028)
        8.3.4 South Korea Graft Versus Host Disease Treatment Market Size and Forecast (2017-2028)
        8.3.5 India Graft Versus Host Disease Treatment Market Size and Forecast (2017-2028)
        8.3.6 Southeast Asia Graft Versus Host Disease Treatment Market Size and Forecast (2017-2028)
        8.3.7 Australia Graft Versus Host Disease Treatment Market Size and Forecast (2017-2028)

9 South America by Country, by Type, and by Application
    9.1 South America Graft Versus Host Disease Treatment Revenue by Type (2017-2028)
    9.2 South America Graft Versus Host Disease Treatment Revenue by Application (2017-2028)
    9.3 South America Graft Versus Host Disease Treatment Market Size by Country
        9.3.1 South America Graft Versus Host Disease Treatment Revenue by Country (2017-2028)
        9.3.2 Brazil Graft Versus Host Disease Treatment Market Size and Forecast (2017-2028)
        9.3.3 Argentina Graft Versus Host Disease Treatment Market Size and Forecast (2017-2028)

10 Middle East & Africa by Country, by Type, and by Application
    10.1 Middle East & Africa Graft Versus Host Disease Treatment Revenue by Type (2017-2028)
    10.2 Middle East & Africa Graft Versus Host Disease Treatment Revenue by Application (2017-2028)
    10.3 Middle East & Africa Graft Versus Host Disease Treatment Market Size by Country
        10.3.1 Middle East & Africa Graft Versus Host Disease Treatment Revenue by Country (2017-2028)
        10.3.2 Turkey Graft Versus Host Disease Treatment Market Size and Forecast (2017-2028)
        10.3.3 Saudi Arabia Graft Versus Host Disease Treatment Market Size and Forecast (2017-2028)
        10.3.4 UAE Graft Versus Host Disease Treatment Market Size and Forecast (2017-2028)

11 Research Findings and Conclusion

12 Appendix
    12.1 Methodology
    12.2 Research Process and Data Source
    12.3 Disclaimer

Table of Figures

List of Tables
    Table 1. Global Graft Versus Host Disease Treatment Revenue by Type, (USD Million), 2017 VS 2021 VS 2028
    Table 2. Global Graft Versus Host Disease Treatment Revenue by Application, (USD Million), 2017 VS 2021 VS 2028
    Table 3. Global Market Graft Versus Host Disease Treatment Revenue (Million USD) Comparison by Region (2017 VS 2021 VS 2028)
    Table 4. Global Graft Versus Host Disease Treatment Revenue (USD Million) by Region (2017-2022)
    Table 5. Global Graft Versus Host Disease Treatment Revenue Market Share by Region (2023-2028)
    Table 6. AbbVie Inc. Corporate Information, Head Office, and Major Competitors
    Table 7. AbbVie Inc. Major Business
    Table 8. AbbVie Inc. Graft Versus Host Disease Treatment Product and Solutions
    Table 9. AbbVie Inc. Graft Versus Host Disease Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
    Table 10. Acrofan Corporate Information, Head Office, and Major Competitors
    Table 11. Acrofan Major Business
    Table 12. Acrofan Graft Versus Host Disease Treatment Product and Solutions
    Table 13. Acrofan Graft Versus Host Disease Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
    Table 14. Astellas Pharma Inc. Corporate Information, Head Office, and Major Competitors
    Table 15. Astellas Pharma Inc. Major Business
    Table 16. Astellas Pharma Inc. Graft Versus Host Disease Treatment Product and Solutions
    Table 17. Astellas Pharma Inc. Graft Versus Host Disease Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
    Table 18. Bristol-Myers Squibb Company Corporate Information, Head Office, and Major Competitors
    Table 19. Bristol-Myers Squibb Company Major Business
    Table 20. Bristol-Myers Squibb Company Graft Versus Host Disease Treatment Product and Solutions
    Table 21. Bristol-Myers Squibb Company Graft Versus Host Disease Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
    Table 22. ElsaLys Biotech SA Corporate Information, Head Office, and Major Competitors
    Table 23. ElsaLys Biotech SA Major Business
    Table 24. ElsaLys Biotech SA Graft Versus Host Disease Treatment Product and Solutions
    Table 25. ElsaLys Biotech SA Graft Versus Host Disease Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
    Table 26. F. Hoffmann-La Roche AG Corporate Information, Head Office, and Major Competitors
    Table 27. F. Hoffmann-La Roche AG Major Business
    Table 28. F. Hoffmann-La Roche AG Graft Versus Host Disease Treatment Product and Solutions
    Table 29. F. Hoffmann-La Roche AG Graft Versus Host Disease Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
    Table 30. Johnson & Johnson Corporate Information, Head Office, and Major Competitors
    Table 31. Johnson & Johnson Major Business
    Table 32. Johnson & Johnson Graft Versus Host Disease Treatment Product and Solutions
    Table 33. Johnson & Johnson Graft Versus Host Disease Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
    Table 34. Mallinckrodft PLC Corporate Information, Head Office, and Major Competitors
    Table 35. Mallinckrodft PLC Major Business
    Table 36. Mallinckrodft PLC Graft Versus Host Disease Treatment Product and Solutions
    Table 37. Mallinckrodft PLC Graft Versus Host Disease Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
    Table 38. Merck & Co., Inc. Corporate Information, Head Office, and Major Competitors
    Table 39. Merck & Co., Inc. Major Business
    Table 40. Merck & Co., Inc. Graft Versus Host Disease Treatment Product and Solutions
    Table 41. Merck & Co., Inc. Graft Versus Host Disease Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
    Table 42. Mesoblast Limited Corporate Information, Head Office, and Major Competitors
    Table 43. Mesoblast Limited Major Business
    Table 44. Mesoblast Limited Graft Versus Host Disease Treatment Product and Solutions
    Table 45. Mesoblast Limited Graft Versus Host Disease Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
    Table 46. Neovii Biotech GmbH Corporate Information, Head Office, and Major Competitors
    Table 47. Neovii Biotech GmbH Major Business
    Table 48. Neovii Biotech GmbH Graft Versus Host Disease Treatment Product and Solutions
    Table 49. Neovii Biotech GmbH Graft Versus Host Disease Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
    Table 50. Novartis AG Corporate Information, Head Office, and Major Competitors
    Table 51. Novartis AG Major Business
    Table 52. Novartis AG Graft Versus Host Disease Treatment Product and Solutions
    Table 53. Novartis AG Graft Versus Host Disease Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
    Table 54. Ocugen, Inc. Corporate Information, Head Office, and Major Competitors
    Table 55. Ocugen, Inc. Major Business
    Table 56. Ocugen, Inc. Graft Versus Host Disease Treatment Product and Solutions
    Table 57. Ocugen, Inc. Graft Versus Host Disease Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
    Table 58. Pfizer Inc Corporate Information, Head Office, and Major Competitors
    Table 59. Pfizer Inc Major Business
    Table 60. Pfizer Inc Graft Versus Host Disease Treatment Product and Solutions
    Table 61. Pfizer Inc Graft Versus Host Disease Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
    Table 62. Pluristem Therapeutics Inc. Corporate Information, Head Office, and Major Competitors
    Table 63. Pluristem Therapeutics Inc. Major Business
    Table 64. Pluristem Therapeutics Inc. Graft Versus Host Disease Treatment Product and Solutions
    Table 65. Pluristem Therapeutics Inc. Graft Versus Host Disease Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
    Table 66. Samedan Ltd Corporate Information, Head Office, and Major Competitors
    Table 67. Samedan Ltd Major Business
    Table 68. Samedan Ltd Graft Versus Host Disease Treatment Product and Solutions
    Table 69. Samedan Ltd Graft Versus Host Disease Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
    Table 70. Sanofi SA Corporate Information, Head Office, and Major Competitors
    Table 71. Sanofi SA Major Business
    Table 72. Sanofi SA Graft Versus Host Disease Treatment Product and Solutions
    Table 73. Sanofi SA Graft Versus Host Disease Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
    Table 74. Soligenix, Inc. Corporate Information, Head Office, and Major Competitors
    Table 75. Soligenix, Inc. Major Business
    Table 76. Soligenix, Inc. Graft Versus Host Disease Treatment Product and Solutions
    Table 77. Soligenix, Inc. Graft Versus Host Disease Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
    Table 78. Global Graft Versus Host Disease Treatment Revenue (USD Million) by Players (2019, 2020, 2021, and 2022)
    Table 79. Global Graft Versus Host Disease Treatment Revenue Share by Players (2019, 2020, 2021, and 2022)
    Table 80. Breakdown of Graft Versus Host Disease Treatment by Company Type (Tier 1, Tier 2 and Tier 3)
    Table 81. Graft Versus Host Disease Treatment Players Head Office, Products and Services Provided
    Table 82. Graft Versus Host Disease Treatment Mergers & Acquisitions in the Past Five Years
    Table 83. Graft Versus Host Disease Treatment New Entrants and Expansion Plans
    Table 84. Global Graft Versus Host Disease Treatment Revenue (USD Million) by Type (2017-2022)
    Table 85. Global Graft Versus Host Disease Treatment Revenue Share by Type (2017-2022)
    Table 86. Global Graft Versus Host Disease Treatment Revenue Forecast by Type (2023-2028)
    Table 87. Global Graft Versus Host Disease Treatment Revenue by Application (2017-2022)
    Table 88. Global Graft Versus Host Disease Treatment Revenue Forecast by Application (2023-2028)
    Table 89. North America Graft Versus Host Disease Treatment Revenue by Type (2017-2022) & (USD Million)
    Table 90. North America Graft Versus Host Disease Treatment Revenue by Type (2023-2028) & (USD Million)
    Table 91. North America Graft Versus Host Disease Treatment Revenue by Application (2017-2022) & (USD Million)
    Table 92. North America Graft Versus Host Disease Treatment Revenue by Application (2023-2028) & (USD Million)
    Table 93. North America Graft Versus Host Disease Treatment Revenue by Country (2017-2022) & (USD Million)
    Table 94. North America Graft Versus Host Disease Treatment Revenue by Country (2023-2028) & (USD Million)
    Table 95. Europe Graft Versus Host Disease Treatment Revenue by Type (2017-2022) & (USD Million)
    Table 96. Europe Graft Versus Host Disease Treatment Revenue by Type (2023-2028) & (USD Million)
    Table 97. Europe Graft Versus Host Disease Treatment Revenue by Application (2017-2022) & (USD Million)
    Table 98. Europe Graft Versus Host Disease Treatment Revenue by Application (2023-2028) & (USD Million)
    Table 99. Europe Graft Versus Host Disease Treatment Revenue by Country (2017-2022) & (USD Million)
    Table 100. Europe Graft Versus Host Disease Treatment Revenue by Country (2023-2028) & (USD Million)
    Table 101. Asia-Pacific Graft Versus Host Disease Treatment Revenue by Type (2017-2022) & (USD Million)
    Table 102. Asia-Pacific Graft Versus Host Disease Treatment Revenue by Type (2023-2028) & (USD Million)
    Table 103. Asia-Pacific Graft Versus Host Disease Treatment Revenue by Application (2017-2022) & (USD Million)
    Table 104. Asia-Pacific Graft Versus Host Disease Treatment Revenue by Application (2023-2028) & (USD Million)
    Table 105. Asia-Pacific Graft Versus Host Disease Treatment Revenue by Region (2017-2022) & (USD Million)
    Table 106. Asia-Pacific Graft Versus Host Disease Treatment Revenue by Region (2023-2028) & (USD Million)
    Table 107. South America Graft Versus Host Disease Treatment Revenue by Type (2017-2022) & (USD Million)
    Table 108. South America Graft Versus Host Disease Treatment Revenue by Type (2023-2028) & (USD Million)
    Table 109. South America Graft Versus Host Disease Treatment Revenue by Application (2017-2022) & (USD Million)
    Table 110. South America Graft Versus Host Disease Treatment Revenue by Application (2023-2028) & (USD Million)
    Table 111. South America Graft Versus Host Disease Treatment Revenue by Country (2017-2022) & (USD Million)
    Table 112. South America Graft Versus Host Disease Treatment Revenue by Country (2023-2028) & (USD Million)
    Table 113. Middle East & Africa Graft Versus Host Disease Treatment Revenue by Type (2017-2022) & (USD Million)
    Table 114. Middle East & Africa Graft Versus Host Disease Treatment Revenue by Type (2023-2028) & (USD Million)
    Table 115. Middle East & Africa Graft Versus Host Disease Treatment Revenue by Application (2017-2022) & (USD Million)
    Table 116. Middle East & Africa Graft Versus Host Disease Treatment Revenue by Application (2023-2028) & (USD Million)
    Table 117. Middle East & Africa Graft Versus Host Disease Treatment Revenue by Country (2017-2022) & (USD Million)
    Table 118. Middle East & Africa Graft Versus Host Disease Treatment Revenue by Country (2023-2028) & (USD Million)
List of Figures
    Figure 1. Graft Versus Host Disease Treatment Picture
    Figure 2. Global Graft Versus Host Disease Treatment Revenue Market Share by Type in 2021
    Figure 3. Etanercept
    Figure 4. Monoclonal Antibodies
    Figure 5. Thalidomide
    Figure 6. Tyrosine Kinase Inhibitors
    Figure 7. mTOR Inhibitors
    Figure 8. Graft Versus Host Disease Treatment Revenue Market Share by Application in 2021
    Figure 9. Acute GVHD Picture
    Figure 10. Chronic GVHD Picture
    Figure 11. Prophylaxis GVHD Picture
    Figure 12. Global Graft Versus Host Disease Treatment Market Size, (USD Million): 2017 VS 2021 VS 2028
    Figure 13. Global Graft Versus Host Disease Treatment Revenue and Forecast (2017-2028) & (USD Million)
    Figure 14. Global Graft Versus Host Disease Treatment Revenue Market Share by Region (2017-2028)
    Figure 15. Global Graft Versus Host Disease Treatment Revenue Market Share by Region in 2021
    Figure 16. North America Graft Versus Host Disease Treatment Revenue (USD Million) and Growth Rate (2017-2028)
    Figure 17. Europe Graft Versus Host Disease Treatment Revenue (USD Million) and Growth Rate (2017-2028)
    Figure 18. Asia-Pacific Graft Versus Host Disease Treatment Revenue (USD Million) and Growth Rate (2017-2028)
    Figure 19. South America Graft Versus Host Disease Treatment Revenue (USD Million) and Growth Rate (2017-2028)
    Figure 20. Middle East and Africa Graft Versus Host Disease Treatment Revenue (USD Million) and Growth Rate (2017-2028)
    Figure 21. Graft Versus Host Disease Treatment Market Drivers
    Figure 22. Graft Versus Host Disease Treatment Market Restraints
    Figure 23. Graft Versus Host Disease Treatment Market Trends
    Figure 24. AbbVie Inc. Recent Developments and Future Plans
    Figure 25. Acrofan Recent Developments and Future Plans
    Figure 26. Astellas Pharma Inc. Recent Developments and Future Plans
    Figure 27. Bristol-Myers Squibb Company Recent Developments and Future Plans
    Figure 28. ElsaLys Biotech SA Recent Developments and Future Plans
    Figure 29. F. Hoffmann-La Roche AG Recent Developments and Future Plans
    Figure 30. Johnson & Johnson Recent Developments and Future Plans
    Figure 31. Mallinckrodft PLC Recent Developments and Future Plans
    Figure 32. Merck & Co., Inc. Recent Developments and Future Plans
    Figure 33. Mesoblast Limited Recent Developments and Future Plans
    Figure 34. Neovii Biotech GmbH Recent Developments and Future Plans
    Figure 35. Novartis AG Recent Developments and Future Plans
    Figure 36. Ocugen, Inc. Recent Developments and Future Plans
    Figure 37. Pfizer Inc Recent Developments and Future Plans
    Figure 38. Pluristem Therapeutics Inc. Recent Developments and Future Plans
    Figure 39. Samedan Ltd Recent Developments and Future Plans
    Figure 40. Sanofi SA Recent Developments and Future Plans
    Figure 41. Soligenix, Inc. Recent Developments and Future Plans
    Figure 42. Global Graft Versus Host Disease Treatment Revenue Share by Players in 2021
    Figure 43. Graft Versus Host Disease Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2021
    Figure 44. Global Top 3 Players Graft Versus Host Disease Treatment Revenue Market Share in 2021
    Figure 45. Global Top 10 Players Graft Versus Host Disease Treatment Revenue Market Share in 2021
    Figure 46. Key Players Market Share Trend (Top 3 Market Share: 2020 VS 2021 VS 2022)
    Figure 47. Global Graft Versus Host Disease Treatment Revenue Share by Type in 2021
    Figure 48. Global Graft Versus Host Disease Treatment Market Share Forecast by Type (2023-2028)
    Figure 49. Global Graft Versus Host Disease Treatment Revenue Share by Application in 2021
    Figure 50. Global Graft Versus Host Disease Treatment Market Share Forecast by Application (2023-2028)
    Figure 51. North America Graft Versus Host Disease Treatment Sales Market Share by Type (2017-2028)
    Figure 52. North America Graft Versus Host Disease Treatment Sales Market Share by Application (2017-2028)
    Figure 53. North America Graft Versus Host Disease Treatment Revenue Market Share by Country (2017-2028)
    Figure 54. United States Graft Versus Host Disease Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
    Figure 55. Canada Graft Versus Host Disease Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
    Figure 56. Mexico Graft Versus Host Disease Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
    Figure 57. Europe Graft Versus Host Disease Treatment Sales Market Share by Type (2017-2028)
    Figure 58. Europe Graft Versus Host Disease Treatment Sales Market Share by Application (2017-2028)
    Figure 59. Europe Graft Versus Host Disease Treatment Revenue Market Share by Country (2017-2028)
    Figure 60. Germany Graft Versus Host Disease Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
    Figure 61. France Graft Versus Host Disease Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
    Figure 62. United Kingdom Graft Versus Host Disease Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
    Figure 63. Russia Graft Versus Host Disease Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
    Figure 64. Italy Graft Versus Host Disease Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
    Figure 65. Asia-Pacific Graft Versus Host Disease Treatment Sales Market Share by Type (2017-2028)
    Figure 66. Asia-Pacific Graft Versus Host Disease Treatment Sales Market Share by Application (2017-2028)
    Figure 67. Asia-Pacific Graft Versus Host Disease Treatment Revenue Market Share by Region (2017-2028)
    Figure 68. China Graft Versus Host Disease Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
    Figure 69. Japan Graft Versus Host Disease Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
    Figure 70. South Korea Graft Versus Host Disease Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
    Figure 71. India Graft Versus Host Disease Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
    Figure 72. Southeast Asia Graft Versus Host Disease Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
    Figure 73. Australia Graft Versus Host Disease Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
    Figure 74. South America Graft Versus Host Disease Treatment Sales Market Share by Type (2017-2028)
    Figure 75. South America Graft Versus Host Disease Treatment Sales Market Share by Application (2017-2028)
    Figure 76. South America Graft Versus Host Disease Treatment Revenue Market Share by Country (2017-2028)
    Figure 77. Brazil Graft Versus Host Disease Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
    Figure 78. Argentina Graft Versus Host Disease Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
    Figure 79. Middle East and Africa Graft Versus Host Disease Treatment Sales Market Share by Type (2017-2028)
    Figure 80. Middle East and Africa Graft Versus Host Disease Treatment Sales Market Share by Application (2017-2028)
    Figure 81. Middle East and Africa Graft Versus Host Disease Treatment Revenue Market Share by Country (2017-2028)
    Figure 82. Turkey Graft Versus Host Disease Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
    Figure 83. Saudi Arabia Graft Versus Host Disease Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
    Figure 84. UAE Graft Versus Host Disease Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
    Figure 85. Methodology
    Figure 86. Research Process and Data Source

Research Methodology

Client Requirements

Review and analyze client requirements

Discussion of all the project requirements and queries

Flexibility Check

Project Feasibility Analysis

Finalizing tentative research programme

Structuring project proposal with scope, timeline, and costs

Analyzing Market Dynamics

Determination of key drivers, restraints, challenge, and opportunity

Identifies market needs and trends

Market Size Estimation & Forecast

Estimation of historical data based on secondary and primary data

Anticipating market recast by assigning weightage to market forces (drivers, restraints, opportunities)

Freezing historical and forecast market size estimations based on evolution, trends, outlook, and strategies

Consideration of geography, region-specific product/service demand for region segments

Consideration of product utilization rates, product demand outlook for segments by application or end-user.

Data Source

Secondary Source
Data collections from annual reports, presentations,associations, journals, analyst reports, paid database, press releases, blogs, newsletters,and GIR repositories.

Primary Source
Research discussion with manufacturers, distributors, suppliers, end user, industry experts to verify insights.

Validation and
triangulation of
secondary and primary source.

Collection of data

Cumulating and collating the essential qualitative and quantitative data

Generation of report in client requested format by research analysts

Reviews by expert analysts

Final quality check

Clarifying queries

Receiving feedback

Ensuring satisfaction

01 Identification of data

This step involves identification of several primary and secondary data research sources, including Global Info Research's internal data sources. The primary sources consist of in-depth discussions and interviews with policy makers, industry experts, and data evaluators, whereas secondary sources include a thorough study of market journals, press releases, annual reports, and government and non-government agencies websites.
02 Evaluation of Market Dynamic

This phase includes a detailed evaluation of several factors that are likely to affect the market dynamics. It involves a comprehensive assessment of major market pain points, drivers, and trends. It also comprises a detailed study of research plans and methodology.
03 Collection of Data

This process consists of gathering data, accessing proprietary databases, and reaching out to key industry participants that operate in the market across the value chain. It also involves studying several patterns in the historical data and comparing it with the current scenario.
04 Collaboration of Data

This stage involves the validation of data and arrival at actual statistics, and evolution of the market over the years. It entails the study and analyzes various segments and verticals of the market. An impact analysis is also performed to observe which factors will affect the market in the next few years.
05 Verification and Analysis

This is the final stage, which involves both quantity and quality checks. Although the process of data verification is an integral part of the research process, all data points and statistics and figures are re-checked to uphold their authenticity and validity.

Companies Mentioned

AbbVie Inc.
Acrofan
Astellas Pharma Inc.
Bristol-Myers Squibb Company
ElsaLys Biotech SA
F. Hoffmann-La Roche AG
Johnson & Johnson
Mallinckrodft PLC
Merck & Co., Inc.
Mesoblast Limited
Neovii Biotech GmbH
Novartis AG
Ocugen, Inc.
Pfizer Inc
Pluristem Therapeutics Inc.
Samedan Ltd
Sanofi SA
Soligenix, Inc.

Related Reports

Global Graft Versus Host Disease Treatment Supply, Demand and Key Producers, 2023-2029

Global Graft Versus Host Disease Treatment Supply, Demand and Key Producers, 2023-2029

date 05 Feb 2023

date Medical Care

The global Graft Versus Host Disease Treatment market size is expected to reach $ million by 2029, rising at a market growth of % CAGR during the forecast period (2023-2029).

Global Graft Versus Host Disease Treatment Market 2023 by Company, Regions, Type and Application, Forecast to 2029

Global Graft Versus Host Disease Treatment Market 2023 by Company, Regions, Type and Application, Forecast to 2029

date 04 Jan 2023

date Medical Care

According to our (Global Info Research) latest study, the global Graft Versus Host Disease Treatment market size was valued at USD million in 2022 and is forecast to a readjusted size of USD million by 2029 with a CAGR of % during review period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.

Global Graft Versus Host Disease Treatment Market 2024 by Company, Regions, Type and Application, Forecast to 2030

Global Graft Versus Host Disease Treatment Market 2024 by Company, Regions, Type and Application, Forecast to 2030

date 23 Jan 2024

date Medical Care

According to our (Global Info Research) latest study, the global Graft Versus Host Disease Treatment market size was valued at USD million in 2023 and is forecast to a readjusted size of USD million by 2030 with a CAGR of % during review period.

Product Tags

graft versus host disease treatment

Organ Rejection Prophylaxis Treatment

Biologics Analytical Services

Purchase Options

Single User License

USD3480.00

Multi User License

USD5220.00

Corporate Users License

USD6960.00

Add To Cart

Buy Now

Popular Product Keywords

AI
semiconductor
electron
5G
artificial intelligence
Battery
new energy
We Provide Professional, Accurate Market Analysis to Help You Stay Ahead of Your Competition.

Speak to our analyst >>
Our Clients
What We Can Provide?

With better results and higher quality products,Our professional reports can achieve four things:
- Insight into the industry market information
- Analyze market development needs
- Prospects for future development
- Develop industry investment strategy
Digging deeper into global industry information and providing market strategies.

Contact Us >>